A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2006
11/23/2006	WO2006084888A3 C-terminally pegylated growth hormones
11/23/2006	WO2006081518A3 Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
11/23/2006	WO2005113781A3 Vectors for use in gene and cancer therapy
11/23/2006	WO2005110473A3 Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
11/23/2006	WO2005089797A3 Support system in the form of protein-based nanoparticles for the cell-specific enrichment of pharmaceutically active substances
11/23/2006	WO2005081711A3 Monomethylvaline compounds capable of conjugation to ligands
11/23/2006	WO2004103272A3 Improved cytotoxic agents comprising new maytansinoids
11/23/2006	US20060264578 Reacting a water soluble polymer having terminal hydroxy group such as polyoxyethylene glycol with di(1-benzotriazolyl)carbonate (di-BTC) to form a 1-benzotriazolylcarbonate ester, then reacting with a bioactive agent to form a polymer conjugate; pegylation of proteins, peptides; no phosgene used
11/23/2006	US20060264516 Use of low molecular weight amino alcohols in ophthalmic compositions
11/23/2006	US20060264505 Dermatological compositions
11/23/2006	US20060264502 Agent for treatment of cisplatin-resistant cancer
11/23/2006	US20060264404 Therapeutic phosphonate compounds
11/23/2006	US20060264377 Chemically modified novel erythropoietin stimulating protein compositions and methods
11/23/2006	US20060264356 Increased or improved bioavailability of the active agents for oral, intracolonic, pulmonary, and other routes of administrations
11/23/2006	US20060263831 Interfacial biomaterials for binding ceramic substrates
11/23/2006	US20060263830 Interfacial biomaterials
11/23/2006	US20060263801 Methods of high-throughput screening for internalizing antibodies
11/23/2006	US20060263439 Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
11/23/2006	US20060263437 Pharmaceutical microspheres containing valproic acid for oral administration
11/23/2006	US20060263436 once daily dosage form of itraconazole independent of food intake; melt-extruding a mixture comprising itraconazole and an appropriate water-soluble polymer and subsequently milling
11/23/2006	US20060263432 Polyhydroxyalkanoate-containing magnetic structure, and manufacturing method and use thereof
11/23/2006	US20060263431 Opioid Sustained Release Formulation
11/23/2006	US20060263430 instrument for inducing cytokine and method of inducing cytokine
11/23/2006	US20060263426 Oral administration form for pyridin-2-ylmethysulfinyl-1h-bezimidazoles
11/23/2006	US20060263422 Pharmaceutical composition containing decoy and use of the same
11/23/2006	US20060263411 Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
11/23/2006	US20060263410 Biological method for detoxication of a liquid food medium
11/23/2006	US20060263392 Method for treating neovascularization
11/23/2006	US20060263390 Modified saccharides, conjugates thereof, and their manufacture
11/23/2006	US20060263380 IL-12 as an adjuvant for Bordetella pertussis vaccines
11/23/2006	US20060263379 Bordetella pertussis antigen consisting lipopolysaccharide, pertusis toxin, filamentous hemagglutinin, pertactin or abosrbed to alum; interleukin-12 ; enhances cell-mediated immunity in a host
11/23/2006	US20060263375 Antibody-serum protein hybrids
11/23/2006	US20060263360 Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives
11/23/2006	US20060263347 Lyophilizing an aqueous mixture of a fibrinolytic metalloproteinase, a zinc stabilizer and optionally a bulking agent, in a citric acid or a water soluble citric acid salt buffer and reconstituing said lyophilized composition
11/23/2006	US20060263336 Cell targeting methods and compositions
11/23/2006	US20060263327 Method for the production of a stable injectable formulation made of difficult to dissolve antineoplastic active substances
11/23/2006	US20060263305 Using azithromycin antibiotic
11/23/2006	US20060263303 Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use
11/23/2006	CA2624616A1 Biomass hydrolysate and uses and production thereof
11/23/2006	CA2616906A1 Molecular constructs suitable for targeted conjugates
11/23/2006	CA2611468A1 Peptides whose uptake by cells is controllable
11/23/2006	CA2608690A1 Stable tablet containing droxidopa
11/23/2006	CA2608571A1 Composition for treatment of a detached retina and method of production thereof
11/23/2006	CA2608505A1 Colonic delivery of adsorbents
11/23/2006	CA2608463A1 Compounds, compositions containing such compounds, and methods of treatment of metastatic melanoma and other cancers
11/23/2006	CA2608383A1 Pharmaceutical composition comprising an oleaginous ointment and vitamin d or the derivatives thereof in solubilised form
11/23/2006	CA2607663A1 Compositions and methods for increasing the stability of antibodies
11/23/2006	CA2607305A1 Anti-mesothelin antibodies useful for immunological assays
11/23/2006	CA2606583A1 Aldehyde conjugated flavonoid preparations
11/23/2006	CA2604568A1 Sustained release l-arginine formulations and methods of manufacture and use
11/22/2006	EP1724353A2 Methods of forming protein-linked lipidic microparticles
11/22/2006	EP1724349A1 TIE Ligand Homologues
11/22/2006	EP1724341A1 Novel taste sensation-modifying peptide nas, dna thereof and use of the same
11/22/2006	EP1724287A1 Hyaluronic acid/methotrexate compound
11/22/2006	EP1724280A1 Use of peptides as penetrating cell carriers
11/22/2006	EP1723974A1 Collagen gel and process for producing the same
11/22/2006	EP1723966A2 Oil in water emulsion vaccines
11/22/2006	EP1723953A1 Nutritional supplements
11/22/2006	EP1723431A1 Hybrid nanoparticles including an ln2o3 core and having bioligands, and method for preparing same
11/22/2006	EP1723418A2 Binding agents
11/22/2006	EP1723172A1 Erythropoietin liquid formulation
11/22/2006	EP1723158A2 O,o -amidomalonate and n,o-amidomalonate platinum complexes
11/22/2006	EP1722834A1 Matrix comprising naturally-occurring crosslinked protein backbone
11/22/2006	EP1722822A1 New complexes
11/22/2006	EP1722821A1 Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same
11/22/2006	EP1722820A1 Long-acting solid formulation comprising triptorelin acetate
11/22/2006	EP1722819A2 Method for solubilising peptide mixtures
11/22/2006	EP1722818A2 Photoreactive compound specifically binding to calcium binding proteins
11/22/2006	EP1722816A2 Support system in the form of protein-based nanoparticles for the cell-specific enrichment of pharmaceutically active substances
11/22/2006	EP1722802A1 A medical solution, a method for producing said medical solution and use thereof
11/22/2006	EP1722773A1 Pregabalin composition
11/22/2006	EP1722763A2 Plaster that reduces skin irritation
11/22/2006	EP1722759A2 Chitosan containing solution
11/22/2006	EP1511770B1 Glycoprotein vi-fc fusion protein for the treatment of vascular diseases
11/22/2006	EP1480620B1 (ester)-lysolecithins in liposomes
11/22/2006	EP1476196B1 Oral solid solution formulation of a poorly water-soluble active substance
11/22/2006	EP1469826B1 Osmotic delivery system
11/22/2006	EP1459738A4 Pharmaceutical composition having thrombolytic, anti-inflammatory and cytoprotective properties
11/22/2006	EP1427717B1 Bioprecursors for percutaneous application
11/22/2006	EP1415648B1 Lyophilizing composition of drug-encapsulating polymer micelle and method for preparation thereof
11/22/2006	EP1370575B1 Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
11/22/2006	EP1361899B1 Silicon implants comprising a radionucleotide for use in brachytherapy
11/22/2006	EP1342472B1 Analgesic and anti-inflammatory patches for external use containing 4-biphenylylacetic acid
11/22/2006	EP1315482B1 Water-dispersible encapsulated sterols
11/22/2006	EP1299081B1 Use of oligosaccharides to stimulate beta-endorphin production
11/22/2006	EP1280495B1 3-methoxybenzyl thiourea derivatives and improved lipid compositions containing same
11/22/2006	EP1244401B1 Drug delivery of phase changing formulation
11/22/2006	EP1220682B1 Stabilized liquid polypeptide-containing pharmaceutical compositions
11/22/2006	EP1073462B1 Combined vaccine against Hepatitis A and Hepatitis B
11/22/2006	EP1054674B1 Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
11/22/2006	EP0952819B1 Biologically active composition
11/22/2006	EP0935415B1 In vitro methods for delivering nucleic acids into a cell
11/22/2006	EP0914832B1 Therapeutic material for periodontosis
11/22/2006	EP0871435B1 Sustained release formulation containing three different types of polymers
11/22/2006	CN1867581A Il－21衍生物 Il-21 derivatives
11/22/2006	CN1867580A Compound modified with glycerol derivative
11/22/2006	CN1867360A Novel glp-1 derivatives
11/22/2006	CN1867359A Methylphenidate solution and associated methods of administration and produciton
11/22/2006	CN1867357A Conjugate of a photosensitiser and a bacteriophage
11/22/2006	CN1867344A Pharmaceutical composition comprising oxoplatin, the salts and derivatives thereof

1 ... 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 ... 1712